全球药物遗传学技术市场规模、份额、趋势和成长分析报告（2026-2034）

预计药物基因体学技术市场将从 2025 年的 87.7 亿美元成长到 2034 年的 184.5 亿美元，2026 年至 2034 年的复合年增长率为 8.62%。

随着个人化医疗成为现代医疗保健策略的核心，全球药物基因组学技术市场正经历快速成长。随着人们对药物反应中遗传变异性的认识不断提高，医疗保健系统正日益将基因组检测纳入常规治疗通讯协定。定序技术和生物资讯学工具的进步降低了检测成本，提高了数据准确性，从而促进了其在临床和研究领域的应用。

关键成长要素包括慢性病发病率上升、对标靶治疗的需求不断增长以及政府推行精准医疗计划。製药公司正在利用药理基因组学知识来优化药物研发并最大限度地减少药物不良反应。此外，临床试验的扩展和基因组研究投资的增加正在推动已开发国家和开发中国家的市场成长。

随着人工智慧驱动的分析和次世代定序平台革新基因组解读方式，未来前景依然十分光明。将药物基因组学整合到电子健康记录中，能够简化临床决策流程。随着医保报销机制的完善和监管流程的日益清晰，预计未来几年，药物基因组学在常规临床实践中的更广泛应用将释放巨大的成长潜力。

目录

第一章：引言

第二章执行摘要

第三章 市场变数、趋势与框架

• 市场谱系展望
• 渗透率和成长前景分析
• 价值链分析
• 法律规范
  • 标准与合规性
  • 监管影响分析
• 市场动态
  • 市场驱动因素
  • 市场限制因素
  • 市场机会
  • 市场挑战
• 波特五力分析
• PESTLE分析

第四章：全球药物遗传学技术市场：依治疗领域划分

• 市场分析、洞察与预测
• 肿瘤学
• 神经系统疾病
• 心血管疾病
• 免疫疾病
• 感染疾病
• 其他的

第五章 全球药物基因学技术市场：依技术划分

• 市场分析、洞察与预测
• PCR
• 原位杂合反应
• 免疫组织化学
• 定序
• 其他的

第六章 全球药物基因技术市场：依地区划分

• 区域分析
• 北美市场分析、洞察与预测
  • 我们
  • 加拿大
  • 墨西哥
• 欧洲市场分析、洞察与预测
  • 英国
  • 法国
  • 德国
  • 义大利
  • 俄罗斯
  • 其他欧洲国家
• 亚太市场分析、洞察与预测
  • 印度
  • 日本
  • 韩国
  • 澳洲
  • 东南亚
  • 亚太其他地区
• 拉丁美洲市场分析、洞察与预测
  • 巴西
  • 阿根廷
  • 秘鲁
  • 智利
  • 其他拉丁美洲国家
• 中东和非洲市场分析、洞察与预测
  • 沙乌地阿拉伯
  • UAE
  • 以色列
  • 南非
  • 其他中东和非洲国家

第七章 竞争情势

• 最新趋势
• 公司分类
• 供应链和销售管道合作伙伴（根据现有资讯）
• 市场占有率和市场定位分析（基于现有资讯）
• 供应商情况（基于现有资讯）
• 策略规划

第八章：公司简介

• 主要公司的市占率分析
• 公司简介
  • QIAGEN
  • GE HealthCare
  • Agilent Technologies Inc
  • FA¢a,A¯Hoffmann La Roche Ltd
  • Foundation Medicine Inc
  • Thermo Fisher Scientific Inc
  • Oxford Nanopore Technologies Plc
  • Twist Bioscience
  • Leica Biosystems Nussloch GmbH
  • Pfizer Inc
  • Abbott Laboratories

The Pharmacogenomics Technology Market size is expected to reach USD 18.45 Billion in 2034 from USD 8.77 Billion (2025) growing at a CAGR of 8.62% during 2026-2034.

The Global Pharmacogenomics Technology Market is witnessing rapid growth as personalized medicine becomes central to modern healthcare strategies. Increasing awareness about genetic variability in drug response is encouraging healthcare systems to integrate genomic testing into routine treatment protocols. Advances in sequencing technologies and bioinformatics tools have reduced testing costs and improved data accuracy, strengthening adoption across clinical and research settings.

Key drivers include rising incidences of chronic diseases, growing demand for targeted therapies, and government initiatives promoting precision medicine programs. Pharmaceutical companies are leveraging pharmacogenomic insights to optimize drug development and minimize adverse drug reactions. Additionally, expanding clinical trials and investments in genomic research are reinforcing market expansion across developed and developing economies.

Future prospects remain highly promising as AI-driven analytics and next-generation sequencing platforms reshape genomic interpretation. Integration of pharmacogenomics into electronic health records will streamline clinical decision-making. As reimbursement frameworks improve and regulatory pathways become clearer, broader implementation in routine clinical practice is expected to unlock significant growth potential in the coming years.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Therapeutic Area

• Oncology
• Neurological Disorders
• Cardiovascular Disease
• Immunological Disorders
• Infectious Diseases
• Others

By Technology

• PCR
• In-situ Hybridization
• Immunohistochemistry
• Sequencing
• Others

COMPANIES PROFILED

• QIAGEN, GE HealthCare, Agilent Technologies Inc, FHoffmann La Roche Ltd, Foundation Medicine Inc, Thermo Fisher Scientific Inc, Oxford Nanopore Technologies plc, Twist Bioscience, Leica Biosystems Nussloch GmbH, Pfizer Inc, Abbott Laboratories
• We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL PHARMACOGENOMICS TECHNOLOGY MARKET: BY THERAPEUTIC AREA 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Therapeutic Area
• 4.2. Oncology Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Neurological Disorders Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.4. Cardiovascular Disease Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.5. Immunological Disorders Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.6. Infectious Diseases Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.7. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL PHARMACOGENOMICS TECHNOLOGY MARKET: BY TECHNOLOGY 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Technology
• 5.2. PCR Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. In-situ Hybridization Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.4. Immunohistochemistry Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.5. Sequencing Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.6. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL PHARMACOGENOMICS TECHNOLOGY MARKET: BY REGION 2022-2034(USD MN)

• 6.1. Regional Outlook
• 6.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 6.2.1 By Therapeutic Area
  • 6.2.2 By Technology
  • 6.2.3 United States
  • 6.2.4 Canada
  • 6.2.5 Mexico
• 6.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 6.3.1 By Therapeutic Area
  • 6.3.2 By Technology
  • 6.3.3 United Kingdom
  • 6.3.4 France
  • 6.3.5 Germany
  • 6.3.6 Italy
  • 6.3.7 Russia
  • 6.3.8 Rest Of Europe
• 6.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 6.4.1 By Therapeutic Area
  • 6.4.2 By Technology
  • 6.4.3 India
  • 6.4.4 Japan
  • 6.4.5 South Korea
  • 6.4.6 Australia
  • 6.4.7 South East Asia
  • 6.4.8 Rest Of Asia Pacific
• 6.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 6.5.1 By Therapeutic Area
  • 6.5.2 By Technology
  • 6.5.3 Brazil
  • 6.5.4 Argentina
  • 6.5.5 Peru
  • 6.5.6 Chile
  • 6.5.7 South East Asia
  • 6.5.8 Rest of Latin America
• 6.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 6.6.1 By Therapeutic Area
  • 6.6.2 By Technology
  • 6.6.3 Saudi Arabia
  • 6.6.4 UAE
  • 6.6.5 Israel
  • 6.6.6 South Africa
  • 6.6.7 Rest of the Middle East And Africa

Chapter 7. COMPETITIVE LANDSCAPE

• 7.1. Recent Developments
• 7.2. Company Categorization
• 7.3. Supply Chain & Channel Partners (based on availability)
• 7.4. Market Share & Positioning Analysis (based on availability)
• 7.5. Vendor Landscape (based on availability)
• 7.6. Strategy Mapping

Chapter 8. COMPANY PROFILES OF GLOBAL PHARMACOGENOMICS TECHNOLOGY INDUSTRY

• 8.1. Top Companies Market Share Analysis
• 8.2. Company Profiles
  • 8.2.1 QIAGEN
  • 8.2.2 GE HealthCare
  • 8.2.3 Agilent Technologies Inc
  • 8.2.4 F.A¢a,A¯Hoffmann La Roche Ltd
  • 8.2.5 Foundation Medicine Inc
  • 8.2.6 Thermo Fisher Scientific Inc
  • 8.2.7 Oxford Nanopore Technologies Plc
  • 8.2.8 Twist Bioscience
  • 8.2.9 Leica Biosystems Nussloch GmbH
  • 8.2.10 Pfizer Inc
  • 8.2.11 Abbott Laboratories